皮佩拉西林/塔扎巴克坦使用与塞费皮姆可能与急性失偿性心力衰竭有关
Hans R Scheerenberger1, Susan Kullab1,2, Ahmed Elgazzar2
1James H. Quillen Veterans Affairs Medical Center, Mountain Home, Tennessee.
概括
与cefepime相比,piperacillin/tazobactam (PTZ) 的使用与心力衰竭 (HF) 恶化和再入院的增加有关. 建议在给有HF病史的患者开PTZ时谨慎使用.
科学领域:
- 传染性疾病 传染性疾病
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮佩拉西林/塔扎巴克坦 (PTZ) 的使用在心脏病患者中通常是有限的,这是由于高含量和对心力衰竭 (HF) 恶化的担忧.
- 之前的研究并没有明确地确定PTZ和HF恶化之间的联系.
研究的目的:
- 调查Piperacillin/tazobactam (PTZ) 使用与急性心力衰竭 (HF) 脱补偿之间的关联.
- 在住院退伍军人中比较PTZ和cefepime之间HF恶化和再入院的发生率.
主要方法:
- 在两年 (2018-2019) 期间,对389名住院退伍军人进行了回顾性审查.
- 对PTZ使用与塞费皮姆相比,对HF急性失补偿的比较.
- 对HF再接收,停留时间和死亡率的分析.
主要成果:
- 在接受PTZ (12.3%) 的患者中,HF的急性失补偿明显高于接受塞费皮姆 (2.2%) 的患者 (P < .001).
- 由于HF恶化导致的重入医院的病例在使用PTZ时也更高 (11对1).
- 两组抗生素之间没有观察到停留时间或总死亡率的显著差异.
结论:
- 与塞费皮姆相比,皮佩拉西林/塔扎巴克坦的使用显著与急性失补偿和因HF恶化而重新入院的发病率增加有关.
- 建议对在医院住院的患者进行仔细监测或避免PTZ,这些患者有HF病史.
更多相关视频
12:03Antimicrobial Synergy Testing by the Inkjet Printer-assisted Automated Checkerboard Array and the Manual Time-kill Method
Published on: April 18, 2019
26.2K
04:05Author Spotlight: Unveiling Prognostic Indicators in Heart Failure - The Role of Phase Angle and Bioelectrical Impedance Analysis
Published on: June 30, 2023
1.8K
相关概念视频
01:27Combined Effects of Drugs: Synergism
3.8K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
3.8K
01:22Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
421
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
421
01:28Pneumonia IV: Management
322
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
322
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
157
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
157
01:22Heart Failure Drugs: Diuretics
363
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
363